BHCM
KITE

Brevan Howard Capital Management’s Kite Pharma, Inc. KITE Stock Holding History

Brevan Howard Capital Management’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$1.15M Buy
+6,408
New +$893K 2.65% 11

Other funds holding KITE

CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Brevan Howard Capital Management's KITE Position: Q3 2017 in Review

Brevan Howard Capital Management opened a new position in Kite Pharma, Inc. (KITE) in Q3 2017: 6,408 shares worth $1.15M. The stake represents 2.65% of the portfolio and ranks #11 among its holdings.

244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

  • Brevan Howard Capital Management held 6,408 shares of Kite Pharma, Inc. worth $1.15M as of Q3 2017.
  • Kite Pharma, Inc. was a new Brevan Howard Capital Management position in Q3 2017.
  • Kite Pharma, Inc. made up 2.65% of Brevan Howard Capital Management's portfolio in Q3 2017, its #11 holding.
  • 244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Brevan Howard Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.